These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34786695)

  • 21. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
    Paule I; Sassi H; Habibi A; Pham KP; Bachir D; Galactéros F; Girard P; Hulin A; Tod M
    Orphanet J Rare Dis; 2011 May; 6():30. PubMed ID: 21619673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of community health workers on quality of life in adolescents and young adults with sickle cell disease: The SHIP-HU study.
    Sisler I; McClish DK; Villella A; Valrie C; Smith WR
    Br J Haematol; 2024 Feb; 204(2):649-657. PubMed ID: 37779237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
    Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
    Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
    Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia.
    Alvarez OA; Rodriguez-Cortes H; Clay ELJ; Echenique S; Kanter J; Strouse JJ; Buitrago-Mogollon T; Courtlandt C; Noonan L; Osunkwo I
    BMJ Qual Saf; 2023 Oct; 32(10):608-616. PubMed ID: 36972983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease.
    Creary S; Chisolm D; Stanek J; Neville K; Garg U; Hankins JS; O'Brien SH
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28250. PubMed ID: 32386106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
    Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
    Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Hillen HF; Duits AJ
    Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.
    Smaldone A; Findley S; Manwani D; Jia H; Green NS
    J Pediatr; 2018 Jun; 197():177-185.e2. PubMed ID: 29571930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Lagunju I; Brown BJ; Sodeinde O
    Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.
    Sasi P; Makubi A; Sangeda RZ; Ngaeje MY; Mmbando BP; Soka J; Rosano C; Magesa AS; Cox SE; Makani J; Novelli EM
    Commun Med (Lond); 2024 Aug; 4(1):160. PubMed ID: 39122788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease.
    Smart LR; Segbefia CI; Latham TS; Stuber SE; Amissah-Arthur KN; Dzefi-Tettey K; Lane AC; Dei-Adomakoh YA; Ware RE
    Trials; 2023 Sep; 24(1):603. PubMed ID: 37737189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R; Lima CS; Grotto HZ
    J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators.
    Pizzo A; Porter JS; Carroll Y; Burcheri A; Smeltzer MP; Beestrum M; Nwosu C; Badawy SM; Hankins JS; Klesges LM; Alberts NM
    Br J Haematol; 2023 Dec; 203(5):712-721. PubMed ID: 37691131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.